MBX
MBX Biosciences, Inc. Common Stock NASDAQ Listed Jan 14, 2000$67.48
After hrs
$67.48
+0.00%
Mkt Cap $3.2B
52w Low $9.63
91.8% of range
52w High $72.64
50d MA $48.54
200d MA $35.21
P/E (TTM)
—
EV/EBITDA
—
P/B
6.7x
Debt/Equity
0.0x
ROE
-23.6%
P/FCF
-31.5x
RSI (14)
64.20
ATR (14)
$4.70
Beta
1.25
50d MA
$48.54
200d MA
$35.21
Avg Volume
863.2K
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
CIK (SEC)
Phone
(317) 659-0200
11711 N. Meridian Street · Carmel, IN 46032 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.64 | -0.49 | +23.4% | 27.95 | -0.5% | +0.2% | +6.4% | -0.2% | -3.5% | -0.9% | — |
| Nov 6, 2025 | AMC | -0.73 | -0.63 | +13.7% | 24.74 | -11.4% | +3.4% | -4.2% | +1.7% | -1.2% | -2.2% | — |
| Aug 7, 2025 | AMC | -0.77 | -0.58 | +24.7% | 11.13 | +0.5% | +9.3% | -7.4% | +11.3% | +3.4% | +2.0% | — |
| May 12, 2025 | AMC | -0.81 | -0.71 | +12.3% | 11.14 | +0.6% | -7.8% | -1.0% | +4.7% | +4.8% | +8.9% | — |
| Mar 17, 2025 | AMC | -0.59 | -0.47 | +20.3% | 8.85 | -2.8% | -4.9% | -0.2% | -5.1% | -1.0% | +3.0% | — |
| Nov 7, 2024 | AMC | -2.72 | -2.78 | -2.2% | 23.22 | +0.4% | -1.3% | +2.6% | -3.3% | -8.2% | -6.5% | — |
| Aug 23, 2024 | AMC | — | -11.47 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | -0.26 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.32 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 16 | Guggenheim | Maintains | Buy → Buy | — | $40.91 | $41.23 | +0.8% | -0.9% | +6.4% | -4.8% | +3.2% | -10.7% |
| Dec 19 | Stifel | Maintains | Buy → Buy | — | $28.67 | $29.33 | +2.3% | +6.1% | +14.4% | -7.5% | -0.3% | -3.8% |
| Nov 10 | Guggenheim | Maintains | Buy → Buy | — | $25.57 | $26.20 | +2.5% | -4.2% | +1.7% | -1.2% | -2.2% | +3.0% |
| Sep 24 | Mizuho | Maintains | Outperform → Outperform | — | $18.96 | $19.74 | +4.1% | +6.0% | -13.8% | +1.0% | +2.5% | -2.5% |
| Sep 23 | Guggenheim | Maintains | Buy → Buy | — | $20.00 | $19.99 | -0.1% | -5.2% | +6.0% | -13.8% | +1.0% | +2.5% |
| Sep 23 | Oppenheimer | Maintains | Outperform → Outperform | — | $20.00 | $19.99 | -0.1% | -5.2% | +6.0% | -13.8% | +1.0% | +2.5% |
| Apr 10 | Guggenheim | Maintains | Buy → Buy | — | $6.40 | $6.56 | +2.5% | -2.0% | +18.2% | +0.3% | -0.7% | +1.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 8, 2026 | Azoulay Salomon | Chief Medical Officer | Sell | 15,003 | $38.30 | $575K | 14,769 | -7.73% | -4.53% |
| May 8, 2026 | Azoulay Salomon | Chief Medical Officer | Sell | 55,000 | $38.38 | $2.1M | 14,769 | -7.73% | -4.53% |
| May 6, 2026 | Hawryluk P. Kent | President & CEO | Sell | 607 | $29.54 | $18K | 727,667 | -2.17% | -8.23% |
| May 6, 2026 | Azoulay Salomon | Chief Medical Officer | Sell | 231 | $29.54 | $7K | 14,769 | -2.17% | -8.23% |
8-K
MBX Biosciences, Inc. -- 8-K Filing
Jul 13
8-K · 8.01
!! High
MBX Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 12
8-K · 5.02
!!! Very High
MBX Biosciences, Inc. -- 8-K 5.02: Executive Change
Jun 5
8-K · 8.01
!! High
MBX Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
MBX Biosciences advanced its obesity pipeline with Phase 1 data for MBX 4291, nominated MBX 5765 as lead amycretin candidate, and progressed imapextide Phase 2a trial.
May 11
8-K
Unknown — 8-K Filing
MBX's 2025 clinical validation of its precision peptide platform de-risks its pipeline and positions the company for potential regulatory approvals, making it attractive for investors betting on novel endocrine-metabolic therapies.
Mar 12
8-K · 8.01
!! High
MBX Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
MBX Biosciences completed a successful FDA End-of-Phase 2 meeting for canvuparatide, positioning the once-weekly treatment to advance into Phase 3 trials for chronic hypoparathyroidism in Q3 2026.
Mar 9
8-K · 5.02
!!! Very High
MBX Biosciences, Inc. -- 8-K 5.02: Executive Change
MBX Biosciences replaced CFO Richard Bartram with interim CFO John Smither, effective March 16, 2026, signaling potential leadership transition during a critical period for the company.
Feb 27
8-K · 8.01
!! High
MBX Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
MBX Biosciences sold shares under its ATM program with Jefferies on February 4, 2026, providing capital funding through its previously established November 2025 agreement.
Feb 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 2,936,684 | $88M | Added | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 1,477,592 | $44M | New | Mar 2026 |
| 3 | Aaron Wealth Advisors Llc | 1,168,176 | $35M | Added | Mar 2026 |
| 4 | Braidwell Lp | 1,018,600 | $32M | New | Dec 2025 |
| 5 | Citadel Advisors Llc | 932,833 | $28M | Added | Mar 2026 |
| 6 | Woodline Partners Lp | 900,063 | $27M | Reduced | Mar 2026 |
| 7 | Millennium Management | 564,415 | $17M | Added | Mar 2026 |
| 8 | Stempoint Capital Lp | 499,469 | $15M | New | Mar 2026 |
| 9 | Ubs Group Ag | 346,914 | $10M | Added | Mar 2026 |
| 10 | Vanguard Portfolio Management Llc | 293,295 | $9M | New | Mar 2026 |
| 11 | D.e. Shaw & Co | 288,889 | $9M | Reduced | Mar 2026 |
| 12 | Opaleye Management Inc. | 260,000 | $8M | Added | Dec 2025 |
| 13 | Northern Trust Corp | 210,575 | $6M | Added | Mar 2026 |
| 14 | Soleus Capital Management, L.p. | 178,897 | $5M | Reduced | Mar 2026 |
| 15 | Jpmorgan Chase & Co | 147,057 | $4M | Added | Mar 2026 |
| 16 | Morgan Stanley | 118,052 | $4M | Added | Dec 2025 |
| 17 | Two Sigma Investments, Lp | 115,075 | $3M | Reduced | Mar 2026 |
| 18 | Jane Street Group, Llc | 86,581 | $3M | New | Dec 2025 |
| 19 | Nuveen, Llc | 81,792 | $2M | Added | Mar 2026 |
| 20 | Bank Of New York Mellon Corp | 80,222 | $2M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$3.21B
Enterprise Value
$2.21B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.46x
P/B
6.67x
P/S
—
P/FCF
-31.52x
EV/EBITDA
—
Shares Out
36.5M
Financials (TTM)
Revenue
$0
Net Income
-$86.6M
EBITDA
-$86.4M
Free Cash Flow
-$81.9M
Op Cash Flow
-$79.9M
EPS Basic
$-2.38
EPS Diluted
$-2.20
EPS Forward
$-2.88
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$385.1M
Total Liab.
$15.9M
Total Equity
$369.2M
Cash
$373.7M
LT Debt
$424K
Book Value/Sh
$10.11
Debt/Equity
0.00x
Current Ratio
24.62
Quick Ratio
24.62
Returns & Growth
ROE
-23.6%
ROA
-22.6%
ROIC
-26.5%
Rev Growth YoY
+0.0%
EPS Growth YoY
-28.6%
Price Returns
2W
+17.3%
1M
+22.5%
3M
+138.9%
6M
+96.1%
12M
+491.6%
Technicals
52W High
$72.64
52W Low
$9.63
50d MA
$48.54
200d MA
$35.21
RSI (14)
64.20
ATR (14)
$4.70
Beta
1.25
Avg Volume
863K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$55.33
High
$88.00
Low
$18.00
Median
$55.00
Data updated apr 25, 2026 8:53pm
· Source: financialmodelingprep.com